RAF-265
Metastatic Melanoma
Novartis PharmaceuticalsSmall moleculePhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 73/ 100
Competitive context
104 Active assets in the Metastatic Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib M.D. Anderson Cancer Center | Phase 2 | BBB |
DACARBAZINE Shanghai Junshi Bioscience Co., Ltd. | Phase 4 | BBB |
Ifa Craig L Slingluff, Jr | Phase 2 | BB |
Nivolumab Bristol-Myers Squibb | Phase 4 | BB |
Montanide Isa 51 Ludwig Institute for Cancer Research | Phase 2 | BB |
View all 50 →
Same molecule, other indications
RAF-265 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →